ClinicalTrials.gg
Not yet recruitingNCT07169513MPAUpdated Sep 11, 2025

Mechanistic Study of Anti-Platelet Therapy in Atherosclerosis

An interventional study of Aspirin 75 mg daily and Clopidogrel 75 mg daily in Peripheral Arterial Disease and Silent Atherosclerosis, sponsored by Guy's and St Thomas' NHS Foundation Trust. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Guy's and St Thomas' NHS Foundation Trust · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing aspirin in Peripheral Arterial Disease — 4 open to participants now, 5 under way, none of them phase 3. Aspirin · Peripheral Arterial Disease.

Planned enrollment
10th of 13
60 · median 150
Started
2025
with 1 other
No phase
6 of 13
3 open now
Registered
10th of 13
by date
Lead sponsor
1 of 13
Guy's and St Thomas' NHS Foundation Trust

Among the 13 studies testing aspirin in Peripheral Arterial Disease, this one is the 10th largest by planned enrollment, is one of 2 that started in 2025, is one of 6 with no phase, and was the 10th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

4 of the 13 studies testing aspirin in Peripheral Arterial Disease are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing aspirin in Peripheral Arterial Disease, or all of them as a file.
02

Study summary

Many people have a higher chance of getting heart problems. These individuals include people who are very overweight (obesity), have high blood pressure (hypertension), diabetes, or other health concerns. Heart problems often happen because of a condition called atherosclerosis. This condition is when the arteries, which are the blood vessels carrying blood from the heart, become hard and inflamed (swollen and irritated) at the same time. Atherosclerosis causes arteries narrowing, making it harder for blood to flow through. The signs of atherosclerosis can be mild, like feeling chest pain (called angina) because the heart isn't getting enough blood. In more serious cases, it can lead to a heart attack.

Think of inflammation as the body's natural alarm system. When a person gets hurt or sick, the body releases special chemicals. These chemicals tell the immune system (the body's defence team) to come and help. Their job is to heal the injury or fight off the infection.

While inflammation is usually good, sometimes it can go wrong. Atherosclerosis is one of these conditions where the inflammation in the blood vessels becomes abnormal. This ongoing inflammation can harm the body and lead to various heart problems and other health issues not directly related to the heart.

In atherosclerosis, platelets (cell fragments in our blood that form clots and stop or prevent bleeding) bind to monocytes (a type of white blood cell and a type of phagocyte - part of the immune system) to form clusters called monocyte platelet aggregate (MPA). Studies have shown that people with atherosclerosis have higher levels of the monocytes clustering with the platelets. This aggregate contributes to the worsening of atherosclerosis. Additionally, this aggregate can predict the risk of developing various cardiac diseases.

Anti-platelet (anti-clotting) medications work by stopping platelet function. In this study, investigators are giving participants two different anti-platelet medications to study the effect of these medications on the level of MPA. The target people of our study are the people with silent atherosclerosis (there is an accumulation of lipids in the blood vessels but no signs or symptoms). No existing research demonstrates whether the two most commonly prescribed anti-platelets (aspirin and clopidogrel) can help reduce MPA levels. This study aims to show the effect of anti-platelet medications on the level of MPA and other inflammatory indicators. The two medications are aspirin and clopidogrel. These two drugs are already available in the market and widely used by different patients for different reasons. Aspirin and clopidogrel have different modes of action to stop platelet function.

03

Conditions studied

  • Peripheral Arterial Disease
  • Silent Atherosclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Group 1:

  • Male or female age 18 years or older
  • Willing to participate in the study, and able to give
  • Negative pregnancy test for a childbearing age woman
  • Receiving standard of care
  • Confirmed atherosclerotic cardiovascular risk based on clinical assessment

Group 2:

  • Male or female age 18 years or older
  • Willing to participate in the study, and able to give informed consent
  • Receiving standard of care
  • Negative pregnancy test for a childbearing age woman
  • Confirmed diagnosis of peripheral arterial disease (ankle-brachial index below 0.9) with Rutherford grade 1-3.

Exclusion criteria

Exclusion Criteria:

Group 1:

  • Diabetes
  • Receiving any anti- medications within the last two weeks
  • Receiving any anticoagulant medications within the last two weeks
  • Receiving statin medications within the last two weeks
  • Known major organ dysfunction
  • Significant co-morbidities
  • Pregnancy or lactating woman
  • Unwilling, or unable to give
  • Presence of co-existing disease
  • to aspirin or clopidogrel
  • Severe hepatic impairment ( grade C)
  • Active peptic ulcer
  • Presence of co-existing inflammatory or autoimmune diseases
  • Frequent use of medications known to affect platelet function five days before baseline phlebotomy and during the study

    • Non-steroidal anti-inflammatory drugs (NSAIDs)
    • Antihistamines
    • Selective serotonin reuptake inhibitors
  • Platelet count \< 100 × 109 /L or > 450 × 109 /L
  • Anaemia
  • Any known bleeding diathesis
  • Currently involved in other clinical research studies

Group 2:

  • Diabetes
  • Patients with PAD Rutherford category of more than 3
  • Receiving any anticoagulant medications within the last two weeks
  • Known major organ dysfunction
  • Pregnancy or lactating woman
  • Unwilling, or unable, to give informed consent
  • Hypersensitivity to aspirin or clopidogrel
  • Severe hepatic impairment (Child-Pugh grade C)
  • Active peptic ulcer
  • Presence of co-existing autoimmune disease
  • Frequent use of medications known to affect platelet function five days before baseline phlebotomy and during the study

    • Non-steroidal anti-inflammatory drugs (NSAIDs)
    • Antihistamines
    • Selective serotonin reuptake inhibitors
  • Platelet count \< 100 × 109 /L or > 450 × 109 /L
  • Anaemia
  • Any known bleeding diathesis
  • Currently involved in other clinical research studies
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Aspirin/Clopidogrel

    Drug: Aspirin 75 mg daily · Drug: Clopidogrel 75 mg daily

  • Active comparator
    Clopidogrel/DAPT

    Drug: Clopidgrel 75 mg daily · Drug: Aspirin 75 mg daily + Clopidgrel 75 mg daily

Interventions

06

What researchers measure

Primary outcomes

  1. Monocyte-platelet aggregates (MPAs)

    Changes in the percentages of monocyte-platelet aggregates (MPAs) in two groups of patients following treatment with aspirin and clopidogrel using flow cytometry

    Time frame: Maximum 14 weeks

Secondary outcomes

  1. Monocyte and platelet activation/phenotype

    Measure the effect of aspirin, clopidogrel, and their combination on monocyte and platelet activation/phenotype using flow cytometry

    Time frame: Maximum 14 weeks

  2. Circulating mediators of inflammation

    Measure the influence of aspirin, clopidogrel, and their combination on the level of circulating mediators of inflammation using multiplex Luminex assay

    Time frame: Maximum 14 weeks

  3. Gene expression

    Determine how aspirin, clopidogrel, and their combination modulate gene expression using single-cell RNA sequencing

    Time frame: Maximum 14 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Jul 2026, 9 months later.

Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 9 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2025
First posted
Sep 11, 2025
StartEst.
Oct 1, 2025
Primary completionEst.
Jul 1, 2026
CompletionEst.
Jul 1, 2026
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07169513
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Oct 1, 2025 (estimated)
Primary completion
Jul 1, 2026 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
Sep 11, 2025

Study contacts

Ashish Patel
Contact
ashish.patel@kcl.ac.uk
0442071880216
Eman Al Musalami
Contact
eman.1.al_musalami@kcl.ac.uk

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Clopidogrel

Start the discussion